CSGR's targets for high profitability and sustainable growth
First written in FY2022. 2 of 6 entries say "Restated". Latest entry: FY2024-Q1.
No other company in this theme has enough history to compare yet.
- FY2024-Q1DroppedAnnual report
「The figures for the “number of partner medical institutions” that have entered into contracts for contract processing services or consulting services and are monitored by the Company as key operating metrics, the “number of contract processing orders,” which combines orders for blood-derived processing services and adipose-derived stem cell processing services, and the “operating margin”」
The key metrics disclosed for the quarter no longer included CSGR and its components, and monitoring had returned to the number of affiliated medical institutions, the number of contract processing cases and the operating margin. It was also stated that there had been no material changes to management policies or strategies, but no explicit withdrawal of the CSGR target was stated. - FY2023WorsenedAnnual report
「Fiscal year ending October 2023 Fourth quarter Revenue growth rate △21.2% EBITDA margin 18.9% CSGR △2.3%」
Fourth-quarter CSGR was △2.3%, comprising a revenue growth rate of △21.2% and an EBITDA margin of 18.9%. It fell significantly from 50.7% for the cumulative third-quarter period, and quarterly results fell below the previously stated target levels, including CSGR above 50%. - FY2023-Q3RestatedAnnual report
「CellSource Growth Rate (hereinafter, “CSGR”) was 50.7% (revenue growth rate of 18.6% + EBITDA margin of 32.1%).」
CSGR for the cumulative third-quarter period was 50.7%, comprising a revenue growth rate of 18.6% and an EBITDA margin of 32.1%. The quarterly table states that third-quarter CSGR was 37.7%, with a revenue growth rate of 5.1% and an EBITDA margin of 32.7%, and the policy of using CSGR as a key management indicator remains in place. - FY2023-Q2RestatedAnnual report
「CellSource Growth Rate (hereinafter, “CSGR”) was 59.7% (revenue growth rate of 27.9% + EBITDA margin of 31.8%).」
CSGR for the cumulative second-quarter period was 59.7%, comprising a revenue growth rate of 27.9% and an EBITDA margin of 31.8%. It remained above the target levels of CSGR above 50% and both the revenue growth rate and EBITDA margin above 20%. - FY2023-Q1AdvancedAnnual report
「CSGR = revenue growth rate + EBITDA margin Revenue growth rate: 29.1% EBITDA margin: 34.6% CSGR: 63.7%」
CSGR was 63.7% for the first quarter, comprising a revenue growth rate of 29.1% and an EBITDA margin of 34.6%. Measurable progress toward the CSGR target was presented. - FY2022First statedAnnual report
「CSGR = revenue growth rate + EBITDA margin Target levels (both of the following must be achieved): ・CSGR > 50% ・Revenue growth rate > 20% and EBITDA margin > 20%」
CSGR, combining the revenue growth rate and EBITDA margin, was introduced as an indicator of sustainable growth and enhanced corporate value, and specific target levels were stated for the first time.